Sanofi Buys Antibody Maker Kymab for $1.45B
Related Stories
April 15, 2021
April 15, 2021
Sanofi has agreed to buy U.K. monoclonal antibody developer Kymab in a deal worth as much as $1.45 billion to gain experimental medicines for inflammation diseases as well as cancer.
The French drugmaker will obtain global rights to KY1005, a human monoclonal antibody with a new mechanism of action and the potential to treat a variety of disorders, the Paris-based company said in a statement.
Sanofi has been hunting for acquisitions to bolster its pipeline, and the deal continues the company’s pivot toward treatments targeting the immune system. The Kymab agreement comes after Sanofi agreed to spend $3.4 billion for U.S. biotech company